Top

Clinical and Translational Oncology

Published in:

01-11-2013 | Research Article

Gene diagnosis of micrometastases in regional lymph nodes of patients with stage I non-small cell lung cancer: impact on staging and prognosis

Authors: J. Li, Z.-N. Li, L.-C. Yu, S.-B. Shi, L.-P. Ge, J.-R. Wu, Y.-M. Hu

Published in: Clinical and Translational Oncology | Issue 11/2013

Abstract

Purpose

The long-term survival of patients with completely resected stage I non-small cell lung cancer (NSCLC) is not optimal because of undetected lymph node micrometastasis at the time of surgery. The aim of this study is to evaluate the role of survivin and livin mRNA expression in histopathologically negative lymph nodes of stage I NSCLC patients as markers of micrometastasis.

Methods

Clinical data and tissue samples of primary tumor and lymph nodes were collected from 44 patients with stage I NSCLC. Reverse-transcriptase-PCR (RT-PCR) was used to detect survivin and livin mRNA expression in these tumor and lymph node samples.

Results

Survivin mRNA was detected in all tumors, and livin mRNA was detectable in 39 of the 44 primary tumors. The cut-off values of survivin and livin mRNA levels for diagnosing micrometastasis in lymph nodes were set up according to the expression of survivin and livin mRNA in control lymph nodes. Fifteen (34.1 %) of 44 stage I NSCCL patients had micrometastasis in lymph nodes by survivin and/or livin mRNA positive expression. Survival analysis showed higher rate of cancer recurrences and tumor-related death in patients with lymph node micrometastasis (P < 0.001 and P = 0.001, respectively). Tumor-free survival and overall survival were significantly worse in patients with lymph node micrometastasis compared with those without such micrometastasis (P = 0.007 and P = 0.01, respectively).

Conclusion

RT-RCR assay for survivin and livin mRNA can be considered as useful diagnostic tool for the detection of lymph node micrometastasis for stage I NSCLC patients.

Rena O, Oliaro A, Cavallo A, Filosso PL, Donati G, Di Marzio P et al (2002) Stage I non-small cell lung carcinoma. Really an early stage? Eur J Cardio-Thorac Surg 21:514–519

Mountain CF (1997) Revisions in the international system for stage lung cancer. Chest 111:1710–1717

Rena O, Carsana L, Cristina S, Papalia E, Massera F, Errico L et al (2007) Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance. Eur J Cardio-Thorac Surg 32:863–867

Gu CD, Osaki T, Oyama T, Inoue M, Kodate M, Dobashi K et al (2002) Detection of micrometastatic tumor-cells in pN0 lymph nodes of patients with completely resected non-small cell lung cancer: impact on recurrence and survival. Ann Surg 235:133–139

Wu J, Ohta Y, Minato H, Tsunezuka Y, Oda M, Watanabe Y et al (2001) Nodal occult metastasis in patients with peripheral lung adenocarcinoma of 2.0 cm or less in diameter. Ann Thorac Surg 7:1772–1777

Le Pimpec-Barthes F, Danel C, Lacave R, Ricci S, Bry X, Lancelin F et al (2005) Association of CK 19 mRNA detection of occult cancer cells in mediastinal lymph nodes in non-small cell lung carcinoma and high risk of early recurrence. Eur J Cancer 41:306–312

Marchevsky AM, Qiao JH, Krajisnik S, Mirocha JM, Mckenna RJ (2003) The prognostic significance of intranodal isolated tumor cells and micrometastases in patients with non-small cell lung carcinoma of the lung. J Thorac Cardiovasc Surg 126:551–557

Osaki T, Oyama T, Gu CD, Yamashita T, So T, Takenoyama M et al (2002) Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small cell lung cancer. J Clin Oncol 13:2930–2936

Salerno CT, Frizelle S, Niehans GA, Ho SB, Jakkula M, Kratzke RA et al (1998) Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptas-polymerase chain reaction. Chest 113:1526–1532

10.

Mori M, Mimori K, Inoue H, Barnard GF, Tsuji K, Nanbara S et al (1995) Detection of cancer micrometastases in lymph nodes by reverse transcriptage-polymeras chain reaction. Cancer Res 55:3417–3420

11.

Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H (1996) Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase- polymerase chain reaction. Am J Pathol 148:649–656

12.

Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921

13.

Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22:8581–8589

14.

Kasof GM, Gomes BC (2001) Livin, a novel inhibitor of apoptosis protein family member. J Bio Chem 276:3238–3246

15.

Velculescu VE, Madden SL, Zhang L Lash AE, Yu J, Rago CL et al (1999) Analysis of human transcriptomes. Nat Genet 23:387–388

16.

Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542–547

17.

Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54

18.

Dai CH, Li J, Shi SB, Yu LC, Ge LP, Chen P (2010) Survivin and smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery. Jpn J Clin Oncol 40:327–335

19.

Chen P, Li J, Ge L-P, Dai C-H, Li X-Q (2010) Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients. Respirology 15:501–509

20.

Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM (2000) ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10:1359–1366

21.

Tanabe H, Yagidashi A, Tsuji N, Shijubo Y, Abe S, Watanabe N (2004) Expression of survivin mRNA and livin mRNA in non-small cell lung cancer. Lung Cancer 46:299–304

22.

Gazzanige P, Gradilone A, Giuliani L, Gandini O, Silvestri I, Nofroni I et al (2003) Expression and prognostic significance of livin, survivin and other apoptosis related genes in the progression of superficial bladder cancer. Ann Oncol 14:85–90

23.

Xiang Y, Yao H, Wang S, Hong M, He J, Cao S et al (2006) Prognostic value of survivin and livin in nasopharyngeal carcinoma. Laryngoscope 116:126–130

24.

American Thoracic Society (1983) Clinical staging of primary lung cancer. Am Rev Respir Dis 127:659

25.

Lugo TG, Braun S, Cote RJ, Panted K, Rusch V (2003) Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol 21:2609–2615

26.

Kappler M, Kohler T, Kampf C, Diestelkötter, P, Würl, P, Schmitz M et al (2001) Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer 95:360–363

27.

Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R et al (2001) Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 32:119–125

28.

Zippelius A, Kufer P, Honold G, Köllermann MW, Oberneder R, Schlimok G et al (1997) Limitations of revers-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 15:2701–2708

29.

Cao M, Yie SM, Wu SM, Chen S, Lou B, He X et al (2009) Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis 26:751–758

30.

Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S et al (2006) Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorect Cancer 6:305–311

Title: Gene diagnosis of micrometastases in regional lymph nodes of patients with stage I non-small cell lung cancer: impact on staging and prognosis
Authors: J. Li
Z.-N. Li
L.-C. Yu
S.-B. Shi
L.-P. Ge
J.-R. Wu
Y.-M. Hu
Publication date: 01-11-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 11/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1017-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2013

Assessment of p38α in peripheral blood mononuclear cells (PBMC): a potential blood protein marker of head and neck squamous cell carcinoma

Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma

Identification of novel biomarkers in neuroblastoma associated with the risk for bone marrow metastasis: a pilot study

Definitive radiotherapy for T1 glottic squamous cell carcinoma: a 15-year Cruces University Hospital experience

Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer

Early volumetric change and treatment outcome of metastatic brain tumors after external beam radiotherapy: differential radiotherapy for brain metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer